A PHASE II TRIAL OF ERLOTINIB FOR PREVIOUSLY TREATED JAPANESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS: RESULTS OF THE CENTRAL JAPAN LUNG STUDY GROUP TRIAL (CJLSG0904).

被引：0

作者：

Hase, Tetsunari ^{[1
]}

Morise, Masahiro ^{[1
]}

Taniguchi, Hiroyuki ^{[2
]}

Shindoh, Joe ^{[3
]}

Kojima, Eiji ^{[4
]}

Tanikawa, Yoshimasa ^{[5
]}

Suzuki, Ryujiro ^{[6
]}

Ogasawara, Tomohiko ^{[7
]}

Yamada, Yoshiyuki ^{[8
]}

Ando, Masahiko ^{[9
]}

Kondo, Masashi ^{[1
]}

Saito, Hiroshi ^{[10
]}

Hasegawa, Yoshinori ^{[1
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4648601, Japan

[2] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Aichi, Japan

[3] Ogaki Municipal Hosp, Dept Resp Med, Gifu, Japan

[4] Komaki Municipal Hosp, Dept Resp Med, Gifu, Japan

[5] Toyota Kosei Hosp, Dept Resp Med & Allergy, Toyota, Japan

[6] Toyohashi Municipal Hosp, Dept Resp Med, Toyohashi, Aichi, Japan

[7] Japanese Red Cross Nagoya Daini Hosp, Dept Resp Med, Nagoya, Aichi, Japan

[8] Konan Kosei Hosp, Dept Resp Med, Konan, Aichi, Japan

[9] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan

[10] Aichi Hosp, Aichi Canc Ctr, Dept Resp Med, Nagoya, Aichi, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

erlotinib; phase II; EGFR;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.10-041

引用

页码：S582 / S583

页数：2

共 50 条

[31] Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics
Motoshima, Kohei
Nakamura, Yoichi
Sano, Kazumi
Ikegami, Yoji
Ikeda, Takaya
Mizoguchi, Kosuke
Takemoto, Shinnosuke
Fukuda, Minoru
Nagashima, Seiji
Iida, Tetsuya
Tsukamoto, Kazuhiro
Kohno, Shigeru
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1299 - 1304
[32] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
Tanaka, Hisashi
Taima, Kageaki
Tanaka, Yoshihito
Itoga, Masamichi
Ishioka, Yoshiko
Nakagawa, Hideyuki
Baba, Keisuke
Hasegawa, Yukihiro
Takanashi, Shingo
Tasaka, Sadatomo
MEDICAL ONCOLOGY, 2018, 35 (03)
[33] Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics
Kohei Motoshima
Yoichi Nakamura
Kazumi Sano
Yoji Ikegami
Takaya Ikeda
Kosuke Mizoguchi
Shinnosuke Takemoto
Minoru Fukuda
Seiji Nagashima
Tetsuya Iida
Kazuhiro Tsukamoto
Shigeru Kohno
Cancer Chemotherapy and Pharmacology, 2013, 72 : 1299 - 1304
[34] Phase I and Pharmacokinetic Study of Erlotinib Administered in Combination With Amrubicin in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer
Otani, Sakiko
Hamada, Akinobu
Sasaki, Jiichiro
Wada, Mayuko
Yamamoto, Michiko
Ryuge, Shinichiro
Takakura, Akira
Fukui, Tomoya
Yokoba, Masanori
Mitsufuji, Hisashi
Toyooka, Issei
Maki, Sachiyo
Kimura, Michiko
Hayashi, Nobuatsu
Ishihara, Mikiko
Kasajima, Masashi
Hiyoshi, Yasuhiro
Katono, Ken
Asakuma, Maiko
Igawa, Satoshi
Kubota, Masaru
Katagiri, Masato
Saito, Hideyuki
Masuda, Noriyuki
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (04): : 405 - 410
[35] PHASE I AND PHARMACOKINETIC STUDY OF ERLOTINIB ADMINISTERED IN COMBINATION WITH AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED NON-SMALL CELL LUNG CANCER
Otani, Sakiko
Hamada, Akinobu
Sasaki, Jiichiro
Yamamoto, Michiko
Ryuge, Shinichiro
Takakura, Akira
Fukui, Tomoya
Yokoba, Masanori
Mitsufuji, Hisashi
Toyooka, Issei
Maki, Sachiyo
Kubota, Masaru
Katagiri, Masato
Saito, Hideyuki
Masuda, Noriyuki
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1165 - S1165
[36] Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
Garon, Edward B.
Siegfried, Jill M.
Stabile, Laura P.
Young, Patricia A.
Marquez-Garban, Diana C.
Park, David J.
Patel, Ravi
Hu, Eddie H.
Sadeghi, Saeed
Parikh, Rupesh J.
Reckamp, Karen L.
Adams, Brad
Elashoff, Robert M.
Elashoff, David
Grogan, Tristan
Wang, He-Jing
Dacic, Sanja
Brennan, Meghan
Valdes, Yacgley
Davenport, Simon
Dubinett, Steven M.
Press, Michael F.
Slamon, Dennis J.
Pietras, Richard J.
LUNG CANCER, 2018, 123 : 91 - 98
[37] A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Ichihara, Eiki
Hotta, Katsuyuki
Nogami, Naoyuki
Kuyama, Shoichi
Kishino, Daizo
Fujii, Masanori
Kozuki, Toshiyuki
Tabata, Masahiro
Harada, Daijiro
Chikamori, Kenichi
Aoe, Keisuke
Ueoka, Hiroshi
Hosokawa, Shinobu
Bessho, Akihiro
Hisamoto-Sato, Akiko
Kubo, Toshio
Oze, Isao
Takigawa, Nagio
Tanimoto, Mitsune
Kiura, Katsuyuki
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 486 - 491
[38] A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901)
Yang, Jin-Ji
Zhou, Qing
Yan, Hong-Hong
Zhang, Xu-Chao
Chen, Hua-Jun
Tu, Han-Yan
Wang, Zhen
Xu, Chong-Rui
Su, Jian
Huang, Yi-Sheng
Wang, Bin-Chao
Jiang, Ben-Yuan
Bai, Xiao-Yan
Zhong, Wen-Zhao
Yang, Xue-Ning
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S321 - S321
[39] Phase I/II study of gefitinib (IressaA®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
Han, Ji-Youn
Lee, Soo Hyun
Lee, Geon Kook
Yun, Tak
Lee, Young Joo
Hwang, Kum Hui
Kim, Jin Young
Kim, Heung Tae
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 475 - 483
[40] Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
Eager, R. M.
Cunningham, C. C.
Senzer, N.
Richards, D. A.
Raju, R. N.
Jones, B.
Uprichard, M.
Nemunaitis, J.
CLINICAL ONCOLOGY, 2009, 21 (06) : 464 - 472

← 1 2 3 4 5 →